CLAIMS

A complete listing of all claims in the application follows.

1.- 42. (Canceled)

43. (Previously presented) A method for treating diabetes in a diabetic subject, the method comprising administering to the subject an effective amount of a heterocyclic carbonyl glycine compound which inhibits a hypoxia inducible factor (HIF) hydroxylase, thereby treating diabetes in the subject.

44. (Previously presented) A method for treating hyperglycemia in a hyperglycemic subject, the method comprising administering to the subject an effective amount of a heterocyclic carbonyl glycine compound which inhibits a HIF hydroxylase, thereby treating hyperglycemia in the subject.

45. (Previously presented) A method for decreasing blood glucose levels in a diabetic or hyperglycemic subject, the method comprising administering to the subject an effective amount of a heterocyclic carbonyl glycine compound which inhibits a HIF hydroxylase, thereby decreasing blood glucose levels in the subject.

46. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the HIF hydroxylase is a HIF prolyl hydroxylase.

47. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the subject is a mammal.

48. (Previously presented) The method of claim 47, wherein the mammal is a human.

49. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is [(7-Chloro-3-hydroxy-quinoline-2-carbonyl)-amino]-acetic acid.

50. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is [(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid.

51. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is [(4-Hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid.

52. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is 4-Oxo-1,4-dihydro-[1,10]phenanthroline-3-carboxylic acid.

53. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is [(1-Chloro-4-hydroxy-7-methoxy-isoquinoline-3-carbonyl)-amino]-acetic acid.

54. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is [(3-Hydroxy-6-isopropoxy-quinoline-2-carbonyl)-amino]-acetic acid.

55. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is [(3-Hydroxy-pyridine-2-carbonyl)-amino]-acetic acid.

56. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the compound is [(7-Benzyloxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid methyl ester.

57. (Previously presented) The method of claim 46, wherein the HIF prolyl hydroxylase is selected from the group consisting of EGLN1, EGLN2, and EGLN3.

58. (Previously presented) The method of any one of claims 43, 44, and 45, wherein the heterocyclic carbonyl glycine is a substituted quinoline-2-carboxamide or esters thereof; a substituted isoquinoline-3-carboxamide or esters thereof; a 3-methoxy pyridine carbonyl glycine or esters thereof; a 3-hydroxypyridine carbonyl glycine or esters thereof; or a 5-sulfonamideocarbonyl pyridine carboxylate or esters thereof.